Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 8/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6374272 | 1.00 | FPR2 (0.57) | FPR2L3MBTL1LMNATSHRRAB9A | |
| SCHEMBL6379132 | 0.80 | FPR2 (0.76) | FPR2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL6374202 | 0.80 | FPR2 (0.76) | FPR2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL3450270 | 0.80 | FPR2 (0.76) | FPR2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL6381503 | 0.78 | L3MBTL1 (0.60) | FPR2L3MBTL1LMNATSHRRAB9A | |
| SCHEMBL10097905 | 0.76 | L3MBTL1 (0.61) | L3MBTL1LMNATSHRRAB9ANPC1 | |
| SCHEMBL14952573 | 0.76 | FPR2 (0.65) | FPR2ALDH1A1MEN1KMT2A | |
| SCHEMBL14937926 | 0.76 | FPR2 (0.65) | FPR2ALDH1A1MEN1KMT2A | |
| SCHEMBL18180178 | 0.76 | NAALAD2 (0.78) | FPR2L3MBTL1NPSR1ALDH1A1MEN1 | |
| SCHEMBL19969196 | 0.76 | NAALAD2 (0.78) | FPR2L3MBTL1NPSR1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137230-A1 | Carboxamide derivatives | DORSCH DIETER (DE) | 2005-06-23 | — | — | US | disclosed |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | MERCK PATENT GMBH (DE) | 2004-02-26 | — | — | US | disclosed |
| EP-1341755-A1 | CARBOXYLIC ACID AMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMOURS | MERCK PATENT GmbH (DE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002048099-A1 | CARBOXYLIC ACID AMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMOURS | MERCK PATENT GMBH (DE) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137230-A1 | Carboxamide derivatives | F11, F12, F2 | FPR2 766/4885L3MBTL1 1883/4885LMNA 436/4885 |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | CNR2, CNR1, HCAR2 | FPR2 176/4885L3MBTL1 3965/4885LMNA 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.